Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 434 | 39% |
| 2020 | 6 | 318 | 46% |
| 2021 | 7 | 361 | 51% |
| 2022 | 5 | 250 | 56% |
| 2023 | 4 | 362 | 59% |
| 2024 | 6 | 406 | 62% |
| 2025 from claims | – | 307 248–361 | 63% |
| 2026 forecast | – | 318 249–400 | 63% |
| 2027 forecast | – | 324 240–429 | 64% |
| 2028 forecast | – | 330 234–456 | 64% |
| 2029 forecast | – | 336 228–482 | 65% |
| 2030 forecast | – | 342 224–508 | 65% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Maine; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| Forecast, Medicare FFS | Hospital outpatient |
|---|---|
| 2026 · ~320 | ~320 |
| 2027 · ~320 | ~320 |
| 2028 · ~330 | ~330 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 98 | 8,386−6.8%/yr | −6.8%/yr | 4.6 | 43% | 8,420 in 2030+0.1%/yr |
| New Jersey | 53 | 6,600−1.2%/yr | −1.2%/yr | 6.3 | 53% | 5,800 in 2030−2.1%/yr |
| Pennsylvania | 78 | 5,698−7.3%/yr | −7.3%/yr | 4.2 | 31% | 4,890 in 2030−2.5%/yr |
| Massachusetts | 46 | 2,725−3.2%/yr | −3.2%/yr | 2.9 | 13% | 2,910 in 2030+1.1%/yr |
| Connecticut | 20 | 1,316+0.2%/yr | +0.2%/yr | 3.9 | 19% | 1,290 in 2030−0.3%/yr |
| New Hampshire | 11 | 730−2.7%/yr | −2.7%/yr | 3.2 | 25% | 880 in 2030+3.1%/yr |
| Rhode Island | 5 | 342+2.1%/yr | +2.1%/yr | 3.7 | 20% | 270 in 2030−3.7%/yr |
| Vermont | 3 | 213−6.2%/yr | −6.2%/yr | 1.9 | 0% | 320 in 2030+7.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 11 | 5,521+56%/yr | +56%/yr | 35.47.6× | 0% | 540 in 2030−32%/yr |
| Hysterectomy, hysteroscopy & ablation | 3 | 290−6%/yr | −6%/yr | 2.00.6× | 7% | 370 in 2030+4%/yr |
| Incontinence, prolapse & sacral neuromodulation | 2 | 101−14%/yr | −14%/yr | 0.60.3× | 0% | 40 in 2030−13%/yr |
BPH procedures in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
Teleflex leads with 50% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 4 companies reported engagement with Maine’s surgeons worth $2,096 in consulting, speaking, meals and travel tied to these products, about $349 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.